MedTrace Logo

Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions

NCT00835042 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-08-20

Study results available
· View outcomes & findings →

Summary

The objective of this study is to compare the relative bioavailability of Moexipril HCl/hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult non-smoking subjects under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Moexipril HCl/hydrochlorothiazide 15/25 mg tablets

1 x 15/25 mg

DRUG

UNIRETIC® 15/25 mg tablets

1 x 15/25 mg

Sponsors & Collaborators

  • Teva Pharmaceuticals USA

    lead INDUSTRY

Principal Investigators

  • Steven Herrmann, M.D.; Ph. D. · Gateway Medical Research

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2003-11-30
Completion
2003-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00835042 on ClinicalTrials.gov